Scinai Immunotherapeutics (SCNI) Short term Debt (2019 - 2025)

Scinai Immunotherapeutics has disclosed Short term Debt across 7 years of filings, most recently posting $522000.0 for Q4 2025.

• Short term Debt for Q4 2025 came in at $522000.0, up 23.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $522000.0 (up 23.11% YoY), and the FY2025 annual result was $522000.0, up 23.11% from the prior year.
• Short term Debt came in at $522000.0 for Q4 2025 at Scinai Immunotherapeutics, up from $497000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $6.0 billion in Q2 2021 to a low of $364000.0 in Q2 2024.
• The 5-year median for Short term Debt is $424000.0 (2024), against an average of $708.0 million.
• Across the five-year window, Short term Debt tumbled 99.99% in 2021 and soared 36.54% in 2025, its largest moves.
• Scinai Immunotherapeutics' Short term Debt stood at $375000.0 in 2021, then increased by 1.87% to $382000.0 in 2022, then climbed by 3.66% to $396000.0 in 2023, then climbed by 7.07% to $424000.0 in 2024, then rose by 23.11% to $522000.0 in 2025.
• The last three Short term Debt figures came in at $522000.0 (Q4 2025), $497000.0 (Q2 2025), and $424000.0 (Q4 2024), per Business Quant data.